Back to top
more

Matinas Biopharma (MTNB)

(Delayed Data from AMEX)

$0.70 USD

0.70
3,396,448

+0.14 (25.35%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $0.69 -0.01 (-0.82%) 6:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Matinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0% and 265.33%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Matinas Biopharma Holdings, Inc. (MTNB) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0% and 0.65%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Matinas Biopharma Holdings, Inc. (MTNB)

by Zacks Equity Research

Matinas Biopharma Holdings, Inc. (MTNB) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Matinas Biopharma Holdings, Inc. (MTNB) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0% and 87.04%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Matinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Matinas (MTNB) Up on Deal With BioNTech for mRNA Vaccines

by Zacks Equity Research

Matinas BioPharma (MTNB) forms an exclusive partnership with BioNTech (BNTX) to develop and advance novel formulations for mRNA vaccines.

Matinas Biopharma Holdings, Inc. (MTNB) Loses 29.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

Matinas Biopharma Holdings, Inc. (MTNB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Matinas Biopharma Holdings, Inc. (MTNB) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Matinas Biopharma Holdings, Inc. (MTNB) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

by Zacks Equity Research

Matinas Biopharma Holdings, Inc. (MTNB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Matinas Biopharma Holdings, Inc. (MTNB) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Matinas Biopharma Holdings, Inc. (MTNB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Matinas Biopharma Holdings, Inc. (MTNB) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Matinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0.00% and -67.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Matinas BioPharma (MTNB) Looks Good: Stock Adds 8.6% in Session

by Zacks Equity Research

Matinas BioPharma (MTNB) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Matinas Biopharma Holdings, Inc. (MTNB) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Matinas Biopharma Holdings, Inc. (MTNB) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

by Zacks Equity Research

Matinas Biopharma Holdings, Inc. (MTNB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Matinas BioPharma (MTNB) in Focus: Stock Moves 6% Higher

by Zacks Equity Research

Matinas BioPharma (MTNB) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Will Matinas BioPharma Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor of Matinas BioPharma

Matinas Biopharma Holdings Inc (MTNB) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Matinas Biopharma Holdings Inc (MTNB) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Matinas Biopharma Holdings, Inc. (MTNB) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of -33.33% and -100.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Kinjel Shah headshot

Prospects Appear Bright for Small Drug Industry in 2020

by Kinjel Shah

Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity keep small drugmakers afloat in a competitive market.

Matinas Biopharma Holdings, Inc. (MTNB) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Matinas Biopharma Holdings, Inc. (MTNB) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 25.00% and 50.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Will Matinas Biopharma Holdings, Inc. (MTNB) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

Matinas Biopharma Holdings, Inc. (MTNB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.